格隆汇3月27日丨联康生物科技集团(00690.HK)公布年度业绩,截至2024年12月31日止年度,集团收益按年增长14.1%至约5.53亿港元。年内溢利按年飙升16.8%至约8280万港元,创历史新高。该等业绩再次印证集团作为领先生物制药公司的稳固市场地位及其提供可持续高质量增长的能力。拟派末期股息每股股份0.277港仙。博固泰?于2024年1月获批,随后于2024年3月上市,实现销售额...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.